Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

EDIT : 36.06 (+5.56%)
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday,...

EDIT : 36.06 (+5.56%)
Editas Medicine Announces First Quarter 2018 Results and Update

Expanded Celgene collaboration to drive lead oncology program in solid tumors

EDIT : 36.06 (+5.56%)
CELGZ : 0.25 (unch)
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from research collaborations, have been accepted for presentation at...

EDIT : 36.06 (+5.56%)
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update...

EDIT : 36.06 (+5.56%)
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately.

PODD : 89.16 (+1.91%)
EDIT : 36.06 (+5.56%)
New Research: Key Drivers of Growth for Editas Medicine, Magellan Health, The RMR Group, Marcus, Nordson, and USA Compression Partners, LP -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas Medicine, Inc. (NASDAQ:EDIT),...

NDSN : 127.00 (-1.74%)
RMR : 75.80 (+0.60%)
USAC : 18.26 (+0.11%)
MGLN : 89.15 (-0.34%)
EDIT : 36.06 (+5.56%)
MCS : 31.60 (-1.71%)
Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million

Flagship Pioneering, a unique life science innovation enterprise, today unveiled Foghorn Therapeutics. Foghorn uses its proprietary Gene Traffic Control(TM) product platform to discover and develop drugs...

SYRS : 11.93 (-0.25%)
MCRB : 8.11 (+1.63%)
DNLI : 20.34 (+1.70%)
EDIT : 36.06 (+5.56%)
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

BLUE : 189.40 (+2.02%)
SRPT : 88.96 (-0.29%)
EDIT : 36.06 (+5.56%)
ALGN : 308.20 (+3.47%)
NTLA : 25.58 (+4.07%)
Why Sarepta (SRPT) Jumped and We Sold

Why Sarepta (SRPT) Jumped and We Sold

SRPT : 88.96 (-0.29%)
BLUE : 189.40 (+2.02%)
EDIT : 36.06 (+5.56%)
ALGN : 308.20 (+3.47%)
NTLA : 25.58 (+4.07%)
Why Sarepta (SRPT) Jumped and We Sold

Why Sarepta (SRPT) Jumped and We Sold

SRPT : 88.96 (-0.29%)
BLUE : 189.40 (+2.02%)
EDIT : 36.06 (+5.56%)
ALGN : 308.20 (+3.47%)
NTLA : 25.58 (+4.07%)
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

SGMO : 16.00 (+2.24%)
BLUE : 189.40 (+2.02%)
SRPT : 88.96 (-0.29%)
EDIT : 36.06 (+5.56%)
JUNO : 86.96 (+0.10%)
Healthcare Heroes That Aren't Done Yet

Healthcare Heroes That Aren't Done Yet

SRPT : 88.96 (-0.29%)
BLUE : 189.40 (+2.02%)
EDIT : 36.06 (+5.56%)
ALGN : 308.20 (+3.47%)
NTLA : 25.58 (+4.07%)
Healthcare Heroes That Aren't Done Yet

Healthcare Heroes That Aren't Done Yet

SRPT : 88.96 (-0.29%)
BLUE : 189.40 (+2.02%)
EDIT : 36.06 (+5.56%)
ALGN : 308.20 (+3.47%)
NTLA : 25.58 (+4.07%)
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update

EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing

EDIT : 36.06 (+5.56%)
Editas Medicine, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Editas Medicine, Inc. (NASDAQ: EDIT) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 5:00 PM Eastern Time....

EDIT : 36.06 (+5.56%)
Editas Medicine Supports Rare Disease Day(R) and Joins Global Movement to Raise Important Awareness for Rare Diseases

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease...

EDIT : 36.06 (+5.56%)
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also...

PODD : 89.16 (+1.91%)
EDIT : 36.06 (+5.56%)
Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher

Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.

BIVV : 104.98 (+0.32%)
EDIT : 36.06 (+5.56%)
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement...

ADVM : 6.15 (+3.36%)
EDIT : 36.06 (+5.56%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +2.39 , ABMD +9.17 , AAXN -1.92 , NSP +1.55 , ERI -0.35
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures settled the day with most contracts 2 to 3 3/4 cents lower. The USDA reported a private sale of 140,000 MT of optional origin corn split evenly between 17/18 and 18/19 to Saudi Arabia through their daily reporting system. Estimates ahead...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar